Research programme: glycine transporter 1 inhibitors - AMRI

Drug Profile

Research programme: glycine transporter 1 inhibitors - AMRI

Alternative Names: AMR-GLY-1; AMR-GLY-3; AMR-GLY-6; GlyT-1 inhibitors - AMRI

Latest Information Update: 30 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AMRI
  • Class
  • Mechanism of Action Glycine transporter 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Schizophrenia

Most Recent Events

  • 30 Sep 2016 Research programme: glycine transporter 1 inhibitors - AMRI is available for licensing as of 30 Sep 2016. http://www.amriglobal.com/partnering/
  • 30 Sep 2016 Preclinical trials in Schizophrenia in USA (unspecified route) ((AMRI website, September 2016)
  • 16 Jul 2016 No recent reports of development identified for research development in Schizophrenia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top